By Limitless Consulting
Since February, the most common question from benefits leaders has been a version of the same one: what does TrumpRx do to our GLP-1 spend?
The honest answer is nothing, until you make it do something.
TrumpRx is a cash-pay channel. It routes members to LillyDirect and NovoCare and surfaces a direct price near $199 to $350 a month for drugs that still carry a list price above $1,000. That is real for the member paying cash. It is also invisible to your plan. A purchase through the portal does not run through your PBM, does not count toward the deductible, and does not touch the out-of-pocket maximum. Your plan keeps paying the same inflated claim it paid in January, in parallel, while the member pays out of pocket beside it.
So the pricing everyone is celebrating online sits one layer away from the place your money actually leaves. The manufacturers lowered the consumer price. They did not lower what your PBM bills your plan.
The question worth asking is not whether TrumpRx is cheaper. It is why your plan is still paying the list-minus-spread number when the direct and most-favored-nation economics already exist. Closing that distance is a routing decision, not a policy one. It is the difference between reading the discount and capturing it inside the plan.
We have been routing GLP-1 claims onto these direct and most-favored-nation channels since the portal went live. The savings do not come from the headline. They come from where you send the claim.
If GLP-1 costs are what’s blowing up your plan renewal, showing you the fix is quick and low-commitment.
CVS settles with FTC, agrees to count TrumpRx drug purchases towards insurance | Reuters
